94 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
5 Nov 20
Agios Reports Business Highlights and Third Quarter 2020 Financial Results
7:32am
% increase in TIBSOVO® net product revenue and offset by a decrease in collaboration revenue due to completion of the research and development services … million for the third quarter of 2019. The increase in SG&A expense was primarily attributable to increased workforce expenses, offset by a decrease
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
13 Feb 20
Agios Reports Fourth Quarter and Full Year 2019 Financial Results
7:40am
of TIBSOVO® and were offset by a decline in collaboration revenue due to the recognition of a milestone from Celgene and the upfront payment from CStone … offset by the net proceeds of $277.2 million from the Novemberfollow-on offering and cash inflows of $99.3 million from product sales, stock option
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 Feb 24
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:03am
from the third quarter of 2023, primarily driven by lower customer inventory levels at the end of the fourth quarter of 2023, partially offset … agreement with Alnylam, partially offset by a reduction in expenses associated with the evolution of our research organization and the sale of our
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
1 Nov 18
Agios Reports Third Quarter 2018 Financial Results
7:45am
quarter was primarily driven by U.S. sales of TIBSOVO® and royalty revenue from U.S. sales of IDHIFA®, offset by a decrease in collaboration revenue … agreement with CStone and $29.2 million received from employee stock transactions. This was offset by expenditures to fund operations of $263.0
DEFA14A
y8wldwt7jrvi4er
18 Apr 19
Additional proxy soliciting materials
4:07pm
DEFA14A
ryszxz
10 May 21
Additional proxy soliciting materials
4:18pm
DEFA14A
iribw
7 Apr 14
Additional proxy soliciting materials
12:00am
DEFA14A
gpye 51m06pue
16 Apr 20
Additional proxy soliciting materials
4:04pm
DEFA14A
4ev05o
8 Apr 21
Additional proxy soliciting materials
4:07pm
DEFA14A
haic z6syunm7
21 Dec 20
Additional proxy soliciting materials
5:21pm
8-K
EX-99.1
9eivedptncji7
2 May 24
Agios Reports Business Highlights and First Quarter 2024 Financial Results
7:01am
8-K
EX-99.1
e0llst 13xmfthewajvm
6 Mar 14
Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
12:00am
8-K
EX-99.1
2aawonwmwldayxmw
7 Nov 13
Agios Pharmaceuticals Reports Third Quarter 2013 Financial Results
12:00am